Table 2 Patient background (n = 430)
Before propensity score weighted adjustment | After propensity score weighted adjustment | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All patients | Using nurse home visit programs | Using pharmacist home visit programs | Using nurse home visit programs (weighted by PS for nurse) | Using pharmacist home visit programs (weighted by PS for pharmacist) | |||||||||
(n = 430);n (%) | Patients who used nurse home visit programs (n = 203); n (%) | Patients who did not used nurse home visit programs (n = 227); n (%) | P-value | Patients who used pharmacist home visit programs (n = 182); n (%) | Patients who did not used pharmacist home visit programs (n = 248); n (%) | P-value | Patients who used nurse home visit programs (%) | Patients who did not used nurse home visit programs (%) | P-value | Patients who used pharmacist home visit programs (%) | Patients who did not used pharmacist home visit programs (%) | P-value | |
Gender | 0.013 | 0.073 | 0.924 | 0.950 | |||||||||
Male | 154 (35.8%) | 85 (41.9%) | 69 (30.4%) | 74 (40.7%) | 80 (32.3%) | (34.3%) | (34.0%) | (35.6%) | (35.4%) | ||||
Female | 276 (64.2%) | 118 (58.1%) | 158 (69.6%) | 108 (59.3%) | 168 (67.7%) | (65.7%) | (66.0%) | (64.4%) | (64.6%) | ||||
Mean age (years ± standard deviation) | 85.0 ± 8.3 | 84.3 ± 8.6 | 85.7 ± 8.0 | 0.07 | 84.7 ± 8.1 | 85.2 ± 8.4 | 0.523 | 85.5 ± 8.5 | 84.9 ± 8.1 | 0.298 | 85.3 ± 8.3 | 85.0 ± 8.2 | 0.575 |
Age (years) | 0.004 | 0.177 | 0.909 | 0.976 | |||||||||
65-74 | 55 (12.8%) | 29 (14.3%) | 26 (11.5%) | 22 (12.1%) | 33 (13.3%) | (12.0%) | (12.1%) | (12.9%) | (12.4%) | ||||
75-84 | 126 (29.3%) | 73 (36.0%) | 53 (23.3%) | 62 (34.1%) | 64 (25.8%) | (30.6%) | (31.9%) | (28.8%) | (29.0%) | ||||
≥85 | 249 (57.9%) | 101 (49.8%) | 148 (65.2%) | 98 (53.8%) | 151 (60.9%) | (56.0%) | (56.0%) | (58.3%) | (58.5%) | ||||
Independent ambulation | 199 (46.3%) | 71 (35.0%) | 128 (56.4%) | <0.001 | 91 (50.0%) | 108 (43.5%) | 0.185 | (45.3%) | (45.6%) | 0.925 | (45.9%) | (46.1%) | 0.934 |
Independent drug overview | 115 (26.7%) | 44 (21.7%) | 71 (31.3%) | 0.025 | 54 (29.7%) | 61 (24.6%) | 0.24 | (22.8%) | (24.8%) | 0.482 | (27.4%) | (26.7%) | 0.812 |
Living with family | 381 (88.6%) | 190 (93.6%) | 191 (84.1%) | 0.002 | 155 (85.2%) | 226 (91.1%) | 0.054 | (87.3%) | (88.4%) | 0.626 | (88.7%) | (88.1%) | 0.774 |
Using home visit programs by nurse | 203 (47.2%) | - | - | - | 78 (42.9%) | 125 (50.4%) | 0.121 | - | - | - | (47.7%) | (47.1%) | 0.855 |
Using home visit programs by pharmacist | 182 (42.3%) | 78 (38.4%) | 104 (45.8%) | 0.121 | - | - | - | (41.5%) | (42.2%) | 0.844 | - | - | - |
Underlying medical conditions | |||||||||||||
Constipation | 243 (56.5%) | 113 (55.7%) | 130 (57.3%) | 0.738 | 115 (63.2%) | 128 (51.6%) | 0.017 | 59.6% | 59.4% | 0.955 | 55.4% | 56.2% | 0.818 |
Hypertension | 228 (53.0%) | 84 (41.4%) | 144 (63.4%) | <0.001 | 101 (55.5%) | 127 (51.2%) | 0.379 | 49.5% | 51.8% | 0.513 | 52.8% | 53.2% | 0.907 |
Dementia | 218 (50.7%) | 87 (42.9%) | 131 (57.7%) | 0.002 | 89 (48.9%) | 129 (52.0%) | 0.523 | 52.5% | 54.2% | 0.601 | 50.9% | 51.5% | 0.860 |
Cerebral infarction/transient ischemic attack | 104 (24.2%) | 45 (22.2%) | 59 (26.0%) | 0.355 | 44 (24.2%) | 60 (24.2%) | 0.997 | 26.8% | 24.5% | 0.456 | 24.7% | 25.1% | 0.906 |
Osteoporosis | 95 (22.1%) | 38 (18.7%) | 57 (25.1%) | 0.111 | 47 (25.8%) | 48 (19.4%) | 0.11 | 26.0% | 22.9% | 0.299 | 22.1% | 22.5% | 0.898 |
Diabetes mellitus | 82 (19.1%) | 33 (16.3%) | 49 (21.6%) | 0.16 | 43 (23.6%) | 39 (15.7%) | 0.039 | 20.2% | 19.1% | 0.691 | 19.2% | 19.7% | 0.852 |
Coronary artery disease | 59 (13.7%) | 27 (13.3%) | 32 (14.1%) | 0.811 | 28 (15.4%) | 31 (12.5%) | 0.39 | 13.3% | 15.3% | 0.410 | 11.8% | 13.1% | 0.544 |
Atrial fibrillation | 55 (12.8)% | 29 (14.3%) | 26 (11.5%) | 0.38 | 27 (14.8%) | 28 (11.3%) | 0.277 | 12.9% | 12.3% | 0.776 | 12.7% | 12.2% | 0.816 |
Dyslipidemia | 51 (11.9%) | 17 (8.4%) | 34 (15.0%) | 0.034 | 27 (14.8%) | 24 (9.7%) | 0.102 | 9.9% | 11.8% | 0.358 | 12.2% | 12.6% | 0.847 |
Benign prostatic hypertrophy | 47 (10.9%) | 24 (11.8%) | 23 (10.1%) | 0.575 | 22 (12.1%) | 25 (10.1%) | 0.51 | 10.1% | 11.6% | 0.485 | 9.9% | 10.8% | 0.685 |
Progressive malignancy | 34 (7.9%) | 23 (11.3%) | 11 (4.8%) | 0.013 | 14 (7.7%) | 20 (8.1%) | 0.888 | 7.5% | 7.1% | 0.807 | 7.2% | 7.7% | 0.751 |
Hyperuricemia/gout | 32 (7.4%) | 9 (4.4%) | 23 (10.1%) | 0.025 | 19 (10.4%) | 13 (5.2%) | 0.042 | 9.2% | 7.8% | 0.473 | 8.1% | 8.2% | 0.951 |
Heart failure | 30 (7.0%) | 17 (8.4%) | 13 (5.7%) | 0.282 | 14 (7.7%) | 16 (6.5%) | 0.618 | 5.0% | 7.3% | 0.163 | 6.2% | 5.9% | 0.815 |
Parkinson's Disease/Parkinson's syndrome | 28 (6.5%) | 14 (6.9%) | 14 (6.2%) | 0.76 | 13 (7.1%) | 15 (6.0%) | 0.649 | 7.5% | 7.8% | 0.866 | 6.2% | 6.6% | 0.840 |
Chronic obstructive pulmonary disease | 27 (6.3%) | 19 (9.4%) | 8 (3.5%) | 0.013 | 17 (9.3%) | 10 (4.0%) | 0.025 | 5.9% | 3.8% | 0.156 | 6.0% | 5.2% | 0.592 |
Peripheral artery occlusive disease | 27 (6.3%) | 7 (3.4%) | 20 (8.8%) | 0.022 | 16 (8.8%) | 11 (4.4%) | 0.066 | 4.0% | 5.7% | 0.253 | 6.0% | 5.6% | 0.816 |
Cerebral/subarachnoid hemorrhage | 26 (6.0%) | 11 (5.4%) | 15 (6.6%) | 0.606 | 17 (9.3%) | 9 (3.6%) | 0.014 | 5.2% | 6.4% | 0.452 | 6.0% | 6.3% | 0.846 |
Osteoarthritis | 21 (4.9%) | 6 (3.0%) | 15 (6.6%) | 0.079 | 9 (4.9%) | 12 (4.8%) | 0.96 | 5.6% | 5.0% | 0.658 | 5.1% | 4.9% | 0.919 |
Number of prescriptions (mean ± standard deviation) | 6.1 ± 3.0 | 6.3 ± 3.0 | 5.8 ± 3.0 | 0.065 | 6.6 ± 3.1 | 5.6 ± 2.8 | <0.001 | 6.2 ± 3.0 | 6.0 ± 3.1 | 0.427 | 5.9 ± 3.0 | 6.0 ± 3.0 | 0.879 |